Here’s a round-up of articles on migraine research that made me feel better than that graph:
- A nice summary of migraine and recent research with a strong focus on neuroanatomical findings (what’s up with those white lesions?) in New Scientist. [PDF]
- Teva (the company that makes frovatriptan) is working on a CGRP monoclonal antibody. It’s working for both chronic and high frequency episodic migraine in phase II clinical trials.
- Teva isn’t the only company with a horse in this race. There are at least three other CGRP monoclonal antibodies in development to target the CGRP pathway.